Aastrom Biosciences Announces First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T

[at noodls] – ANN ARBOR, Mich., April 4, 2013 (GLOBE NEWSWIRE) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic … more

View todays social media effects on ASTM

View the latest stocks trending across Twitter. Click to view dashboard

See who Aastrom is hiring next, click here to view